Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Double-Blind, Double-Dummy, Active-Controlled, Cross-Over Study Evaluating the Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura

Trial Profile

Randomized, Double-Blind, Double-Dummy, Active-Controlled, Cross-Over Study Evaluating the Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sumatriptan (Primary) ; Sumatriptan
  • Indications Migraine with aura; Migraine without aura
  • Focus Registrational; Therapeutic Use
  • Acronyms COMPASS
  • Sponsors Avanir Pharmaceuticals; OptiNose
  • Most Recent Events

    • 07 May 2019 Results applying novel analytic approach for measuring consistency of response in the acute treatment of episodic migraine using data from the COMPASS study published in the Headache
    • 16 Oct 2017 Results published in the Headache
    • 10 Sep 2017 Results (n=259) comparing efficacy and tolerability of sumatriptan tablets versus sumatriptan delivered intranasally in adult patients with acute migraine with or without aura, were presented at the 2017 International Headache Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top